Natco Pharma Ltd’s finished dosage formulations (FDF) facility in Visakhapatnam has commenced commercial operations.
The facility is a part of the Special Economic Zone (SEZ) and is intended to cater primarily to the US and other international markets.
“The Vizag facility is a key part of NATCO' s capacity expansion plans for its pipeline of products and entry into new geographies. The facility will focus on oral solid dosages (tablets and capsules), including a cytotoxic block for products in the oncology segment,’’ the Hyderabad-based company said in a release.
An application had been filed with the US Food and Drug Administration (USFDA) for site transfer of the first product and to trigger a regulatory audit, it added.
Natco’s scrip ended flat on the Bombay Stock Exchange on Thursday at Rs 599.40.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.